Literature DB >> 25724694

Expression pattern of RAGE and IGF-1 in the human fetal ovary and ovarian serous carcinoma.

Ana Poljicanin1, Natalija Filipovic1, Tanja Vukusic Pusic2, Violeta Soljic3, Ana Caric1, Mirna Saraga-Babic1, Katarina Vukojevic4.   

Abstract

The expression pattern of RAGE and IGF-1 proteins in different ovarian cell lineages was histologically analyzed in six fetal, nine adult human ovaries, and nine serous ovarian carcinomas (OSC) using immunohistochemical methods. Mild expression of IGF-1 in ovarian surface epithelium (Ose) and oocytes in the 15-week human ovaries increased to moderate or strong in the stromal cells, oocytes and follicular cells in week 22. Occasional mild RAGE expression was observed in Ose during week 15, while strong expression characterized primordial follicles in week 22. In the reproductive human ovary, IGF-1 was mildly to moderately expressed in all ovarian cell lineages except in theca cells of the tertiary follicle where IGF-1 was negative. RAGE was strongly positive in the granulosa cells and some theca cells of the tertiary follicle, while negative to mildly positive in all cells of the secondary follicle. In the postmenopausal human ovary IGF-1 and RAGE were mildly expressed in Ose and stroma. In OSC, cells were strongly positive to IGF-1 and RAGE, except for some negative stromal cells. Different levels of IGF-1 and RAGE co-expression characterized fetal ovarian cells during development. In reproductive ovaries, IGF-1 and RAGE were co-localized in the granulosa and theca interna cells of tertiary follicles, while in postmenopausal ovaries and OSC, IGF-1 and RAGE were co-localized in Ose and OSC cells respectively. Our results indicate that intracellular levels of IGF-1 and RAGE protein might regulate the final destiny of the ovarian cell populations prior and during folliculogenesis, possibly controlling the metastatic potential of OSC as well.
Copyright © 2015. Published by Elsevier GmbH.

Entities:  

Keywords:  Human fetus; IGF-1; Ovary; RAGE; Serous ovarian carcinoma

Mesh:

Substances:

Year:  2015        PMID: 25724694     DOI: 10.1016/j.acthis.2015.01.004

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  4 in total

1.  Expression of the Insulin-like Growth Factor System in First- and Second-Trimester Human Embryonic and Fetal Gonads.

Authors:  Linn Salto Mamsen; Aikaterini Zafeiri; Jane Alrø Bøtkjær; Jonna Rasmussen Hardlei; Erik Ernst; Claus Oxvig; Paul A Fowler; Claus Yding Andersen
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

Review 2.  Role of the Glyoxalase System in Breast Cancer and Gynecological Cancer-Implications for Therapeutic Intervention: a Review.

Authors:  Jingyuan Wang; Xiao Yang; Zhiqi Wang; Jianliu Wang
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

3.  Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer.

Authors:  Gareth D Healey; Belen Pan-Castillo; Jezabel Garcia-Parra; Julia Davies; Shaun Roberts; Eilir Jones; Kalyan Dhar; Sarika Nandanan; Nasima Tofazzal; Luke Piggott; Richard Clarkson; Gillian Seaton; Asa Frostell; Tim Fagge; Colin McKee; Lavinia Margarit; R Steven Conlan; Deyarina Gonzalez
Journal:  J Immunother Cancer       Date:  2019-10-29       Impact factor: 12.469

Review 4.  The ovarian reserve as target of insulin/IGF and ROS in metabolic disorder-dependent ovarian dysfunctions.

Authors:  Maria Dri; Francesca Gioia Klinger; Massimo De Felici
Journal:  Reprod Fertil       Date:  2021-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.